The NEI’s Role in Innovation

The NEI’s Role in Innovation
The National Eye Institute (NEI) spends $675 million annually, mostly on basic science and discovery research.  In addition, said Matthew J. McMahon, PhD, Director of the agency’s Office of Translational Research, “We have a clear mandate to help translate these discoveries into clinical medicine and public health improvements.” He points to the agency’s role in fostering the development of ocular coherence tomography, micro-needle drug delivery, and adaptive optics technologies, for example.

NEI funds researchers, companies, and institutions through non-dilutive grants—either large translational research grants or small business innovation grants—that allow for all intellectual property to be retained by the grant recipients.  Current grants are funding such diverse projects as small molecule-photoswitch research, gene therapy approaches, micro-RNA for sustained anti-VEGF delivery, and the quest for novel new compounds to modulate cannabinoids for glaucoma therapy. Regenerative medicine, optogenetics, and genome editing tools are among the agency’s priorities for upcoming grants.

Speaking at OIS@AAO, McMahon also noted that NEI invests significant resources to fund clinical trials and training for clinician scientists. “That is critical to ensure we have the talent to move innovation forward and combine high quality scientific research with the clinical application that is necessary to develop new technologies,” he said.

For more information, visit www.nei.nih.gov/translational.

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

AbbVie’s Big Bet to Diversify with Allergan Pays Off So Far

AbbVie’s Big Bet to Diversify with Allergan Pays Off So Far

Eyenuk’s EyeArt AI System Showing Its Value

Eyenuk’s EyeArt AI System Showing Its Value

New J&J Vision CMO Steps onto a Very Large Stage

New J&J Vision CMO Steps onto a Very Large Stage

With Fresh Funding, Eyenovia Pursues Platform for Focused Drug Delivery

With Fresh Funding, Eyenovia Pursues Platform for Focused Drug Delivery

Covid-19 Impact on Healthcare Company Valuations & Financings

Covid-19 Impact on Healthcare Company Valuations & Financings

Aldeyra Eyes Lucrative DED, Conjunctivitis Markets

Aldeyra Eyes Lucrative DED, Conjunctivitis Markets

About The Author

Tom Salemi

Tom serves as Content Director for Healthegy, joining the company in 2014, to create and manage a new line of podcasts, publications and other editorial products. At Healthegy, Tom hosts the OIS Podcast and MedtechTalk, contributes to the Engage and Eye on Innovation newsletters and assists in the agenda development of new and existing conferences.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

SUBSCRIBE TO OIS WEEKLY

Get our monthly newsletter about the latest in opthalmologic innovation.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

STAY CONNECTED

NEW VIDEOS

PODCASTS